Clinical Trial

First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy

Name: First-line Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma With Dual Immunotherapy Combined With Chemotherapy — clinical trial record (NCT07400315)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

A prospective, single-arm, multicenter, Phase II clinical study of Apatolimab Tovolimab (QL1706) in combination with modified FLOT regimen (TFOX) as first-line treatment for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma

Trial Details

NCT Number	NCT07400315
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment	64 participants
Start Date	2026-03-01
Primary Completion	2028-12-31 (estimated)
Study Completion	2029-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-10